Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value

Published: October3, 2011
No. of Pages: 169
Price: $ 3500


GBI Research, the leading business intelligence provider, has released its latest research “Metabolic Disorders Therapeutics Market to 2017 – Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value”, which provides insights into metabolic disease therapeutics marled until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major metabolic diseases including Diabetes, Obesity and Dyslipidemia. The report also provides the share of generics in global metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each three indications. The report examines the global metabolic diseases treatment usage patterns. In addition, the geographical distribution of metabolic diseases and market across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the metabolic diseases R&D product pipeline and explores the competitive landscape including major players in metabolic disorder therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in metabolic disorder therapeutics market.

Browse All: Pharmaceuticals Market Research

Scope
• The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global metabolic disorder therapeutics market for the three indications that includes Diabetes, Obesity and Dyslipidemia.
• The report covers:
• Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
• Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2017 for three indications which includes diabetes, obesity and dyslipidemia
• Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
• Share of the generics in global metabolic disorder therapeutics market and for the market of each indication that is covered in the report.
• Key drivers and restraints that have had a significant impact on the market.
• The competitive landscape of the global metabolic disorder market including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Novo Nordisk, Sanofi, Takeda, Eli Lilly, GlaxoSmithKline and Merck & Co. Inc.
• Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorder therapeutics market.

Reasons to Buy
• The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
• Align your product portfolio to the markets with high growth potential.
• Build effective strategies to launch their pipeline products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.